» Articles » PMID: 25728669

Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands

Abstract

Most cell-surface receptors for cytokines and growth factors signal as dimers, but it is unclear whether remodeling receptor dimer topology is a viable strategy to "tune" signaling output. We utilized diabodies (DA) as surrogate ligands in a prototypical dimeric receptor-ligand system, the cytokine Erythropoietin (EPO) and its receptor (EpoR), to dimerize EpoR ectodomains in non-native architectures. Diabody-induced signaling amplitudes varied from full to minimal agonism, and structures of these DA/EpoR complexes differed in EpoR dimer orientation and proximity. Diabodies also elicited biased or differential activation of signaling pathways and gene expression profiles compared to EPO. Non-signaling diabodies inhibited proliferation of erythroid precursors from patients with a myeloproliferative neoplasm due to a constitutively active JAK2V617F mutation. Thus, intracellular oncogenic mutations causing ligand-independent receptor activation can be counteracted by extracellular ligands that re-orient receptors into inactive dimer topologies. This approach has broad applications for tuning signaling output for many dimeric receptor systems.

Citing Articles

Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis.

Shah A, Majeti K, Ekman F, Selvaraj S, Sharma D, Sinha R Nat Commun. 2025; 16(1):1140.

PMID: 39880867 PMC: 11779867. DOI: 10.1038/s41467-025-56239-5.


Structural studies of the IFNλ4 receptor complex using cryoEM enabled by protein engineering.

Grubbe W, Zhang B, Kauffman A, Bylehn F, Padol K, Jung H Nat Commun. 2025; 16(1):818.

PMID: 39827213 PMC: 11742915. DOI: 10.1038/s41467-025-56119-y.


The JAK-STAT pathway: from structural biology to cytokine engineering.

Lv Y, Qi J, Babon J, Cao L, Fan G, Lang J Signal Transduct Target Ther. 2024; 9(1):221.

PMID: 39169031 PMC: 11339341. DOI: 10.1038/s41392-024-01934-w.


Development of a Humanized Antibody Targeting Extracellular HSP90α to Suppress Endothelial-Mesenchymal Transition-Enhanced Tumor Growth of Pancreatic Adenocarcinoma Cells.

Fan C, Hung H, Chen C, Chen L, Ke Y, Yeh T Cells. 2024; 13(13.

PMID: 38994997 PMC: 11240389. DOI: 10.3390/cells13131146.


i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists.

Romei M, Leonard B, Katz Z, Le D, Yang Y, Day E Nat Commun. 2024; 15(1):642.

PMID: 38245524 PMC: 10799922. DOI: 10.1038/s41467-024-44985-x.


References
1.
Pikman Y, Lee B, Mercher T, McDowell E, Ebert B, Gozo M . MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270. PMC: 1502153. DOI: 10.1371/journal.pmed.0030270. View

2.
Verstovsek S, Kantarjian H, Mesa R, Pardanani A, Cortes-Franco J, Thomas D . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363(12):1117-27. PMC: 5187954. DOI: 10.1056/NEJMoa1002028. View

3.
Brooks A, Dai W, OMara M, Abankwa D, Chhabra Y, Pelekanos R . Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014; 344(6185):1249783. DOI: 10.1126/science.1249783. View

4.
Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

5.
Livnah O, Stura E, Johnson D, Middleton S, Mulcahy L, Wrighton N . Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996; 273(5274):464-71. DOI: 10.1126/science.273.5274.464. View